IL215797A0 - Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors - Google Patents

Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors

Info

Publication number
IL215797A0
IL215797A0 IL215797A IL21579711A IL215797A0 IL 215797 A0 IL215797 A0 IL 215797A0 IL 215797 A IL215797 A IL 215797A IL 21579711 A IL21579711 A IL 21579711A IL 215797 A0 IL215797 A0 IL 215797A0
Authority
IL
Israel
Prior art keywords
heteroaromatic
lipase inhibitors
monoacylglycerol lipase
amides
aromatic
Prior art date
Application number
IL215797A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL215797A0 publication Critical patent/IL215797A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL215797A 2009-04-22 2011-10-23 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors IL215797A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17166109P 2009-04-22 2009-04-22
PCT/US2010/032100 WO2010124122A1 (en) 2009-04-22 2010-04-22 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
IL215797A0 true IL215797A0 (en) 2012-01-31

Family

ID=42226535

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215797A IL215797A0 (en) 2009-04-22 2011-10-23 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors

Country Status (11)

Country Link
EP (1) EP2421535A1 (de)
JP (1) JP2012524810A (de)
KR (1) KR20120005517A (de)
CN (1) CN102458407B (de)
AU (1) AU2010238746B2 (de)
BR (1) BRPI1014874A2 (de)
CA (1) CA2759706A1 (de)
IL (1) IL215797A0 (de)
RU (1) RU2011147201A (de)
TW (1) TW201103914A (de)
WO (1) WO2010124122A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049289A1 (en) * 2011-09-30 2013-04-04 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
US9624170B2 (en) 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors
JP6653319B2 (ja) * 2015-03-30 2020-02-26 武田薬品工業株式会社 複素環化合物
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JP6832342B2 (ja) 2016-03-31 2021-02-24 武田薬品工業株式会社 複素環化合物
AR108012A1 (es) 2016-03-31 2018-07-04 Takeda Pharmaceuticals Co Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
CN111148746B (zh) 2017-09-29 2022-08-05 武田药品工业株式会社 杂环化合物
EP3717477B1 (de) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG Neue heterocyclische verbindungen
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
SG11202102281VA (en) * 2018-09-28 2021-04-29 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
EP2180048B1 (de) * 2008-10-09 2014-12-17 Janssen Pharmaceutica N.V. Alternative Kristallform von Monoacylglycerinlipase (MGLL)

Also Published As

Publication number Publication date
AU2010238746B2 (en) 2015-02-19
JP2012524810A (ja) 2012-10-18
CN102458407A (zh) 2012-05-16
EP2421535A1 (de) 2012-02-29
AU2010238746A1 (en) 2011-11-10
CN102458407B (zh) 2014-03-05
RU2011147201A (ru) 2013-05-27
BRPI1014874A2 (pt) 2016-04-12
KR20120005517A (ko) 2012-01-16
TW201103914A (en) 2011-02-01
CA2759706A1 (en) 2010-10-28
WO2010124122A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
HK1170239A1 (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
IL215797A0 (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
HK1170228A1 (en) Azetidinyl diamides as monoacylglycerol lipase inhibitors
IL225769A0 (en) Piperidine-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
HK1189587A1 (en) Bromodomain inhibitors and uses thereof
EP2456757A4 (de) Hdac-hemmer und therapieverfahren dafür
IL225815A0 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
ZA201202489B (en) Novel heterocyclic acrylamides and their use as pharmaceuticals
SG10201507362TA (en) Novel Regulatory Proteins And Inhibitors
ZA200906212B (en) 5-oxo-isoxazoles as inhibitors of lipases and phospholipases
AP3650A (en) Apolipoprotein l-i variants and their use
EP2623593A4 (de) Neue aminotransferase und dafür kodierendes gen sowie verwendung der aminotransferase und des gens
EP2445895A4 (de) Piperazindithioctat und pharmazeutische zusammensetzung damit
EP2597084A4 (de) N-hydroxyformamidderivat und arzneimittel damit
EP2427766A4 (de) Menschliches fg01-gen und anwendungen dafür
IL214333A0 (en) Carbamoylphosphonates as inhibitors and uses thereof
PL388613A1 (pl) Nowa 7-O-n-pentylo-5-O-metylo-8-prenylonaringenina oraz sposób jej otrzymywania